Medinet, Two Medical Institutions Jointly Launch Clinical Studies of Gamma-delta T Cell Therapy for Multiple Myeloma.
The three partners will jointly undertake through March 2006 clinical studies of lymphokine-activated killer cell therapy using gamma-delta T cells. Specifically, they aim to verify the safety and validity of cell therapy in treating multiple myeloma, a type of blood cancer that develops anemia, renal damage, bone pain and fracture, and hypercalcemia.
Medinet will provide raw data on the therapy to the institutions while analyzing results obtained from the clinical studies.
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Dec 9, 2005|
|Previous Article:||Toshiba Develops MEMS-based Cell Manipulation Method.|
|Next Article:||Rohm and Haas Japan Introduces New Rheology Modifier ACULYN 38.|